ASSEMBLY BIOSCIENCES INC (ASMB) Stock Fundamental Analysis

NASDAQ:ASMB • US0453962070

29.84 USD
+0.25 (+0.84%)
At close: Feb 27, 2026
29.84 USD
0 (0%)
After Hours: 2/27/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

ASMB gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. While ASMB seems to be doing ok healthwise, there are quite some concerns on its profitability. ASMB is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year ASMB has reported negative net income.
  • ASMB had a negative operating cash flow in the past year.
  • In the past 5 years ASMB always reported negative net income.
  • In the past 5 years ASMB reported 4 times negative operating cash flow.
ASMB Yearly Net Income VS EBIT VS OCF VS FCFASMB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

  • With a decent Return On Assets value of -16.06%, ASMB is doing good in the industry, outperforming 78.35% of the companies in the same industry.
  • The Return On Equity of ASMB (-21.10%) is better than 82.57% of its industry peers.
Industry RankSector Rank
ROA -16.06%
ROE -21.1%
ROIC N/A
ROA(3y)-56.64%
ROA(5y)-51.96%
ROE(3y)-127.35%
ROE(5y)-96.95%
ROIC(3y)N/A
ROIC(5y)N/A
ASMB Yearly ROA, ROE, ROICASMB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

  • ASMB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ASMB Yearly Profit, Operating, Gross MarginsASMB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • ASMB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ASMB has been increased compared to 1 year ago.
  • ASMB has more shares outstanding than it did 5 years ago.
  • ASMB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ASMB Yearly Shares OutstandingASMB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
ASMB Yearly Total Debt VS Total AssetsASMB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • ASMB has an Altman-Z score of 0.44. This is a bad value and indicates that ASMB is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 0.44, ASMB is in the better half of the industry, outperforming 61.11% of the companies in the same industry.
  • ASMB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.44
ROIC/WACCN/A
WACC8.61%
ASMB Yearly LT Debt VS Equity VS FCFASMB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

  • A Current Ratio of 4.44 indicates that ASMB has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 4.44, ASMB is in line with its industry, outperforming 50.96% of the companies in the same industry.
  • ASMB has a Quick Ratio of 4.44. This indicates that ASMB is financially healthy and has no problem in meeting its short term obligations.
  • ASMB has a Quick ratio (4.44) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.44
Quick Ratio 4.44
ASMB Yearly Current Assets VS Current LiabilitesASMB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 34.38% over the past year.
  • ASMB shows a strong growth in Revenue. In the last year, the Revenue has grown by 31.30%.
  • ASMB shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.31% yearly.
EPS 1Y (TTM)34.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.32%
Revenue 1Y (TTM)31.3%
Revenue growth 3Y65.83%
Revenue growth 5Y12.31%
Sales Q2Q%57.62%

3.2 Future

  • ASMB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.40% yearly.
  • Based on estimates for the next years, ASMB will show a quite strong growth in Revenue. The Revenue will grow by 19.24% on average per year.
EPS Next Y45.91%
EPS Next 2Y21.3%
EPS Next 3Y32.01%
EPS Next 5Y11.4%
Revenue Next Year38.92%
Revenue Next 2Y-9.79%
Revenue Next 3Y45.02%
Revenue Next 5Y19.24%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ASMB Yearly Revenue VS EstimatesASMB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M 200M 250M
ASMB Yearly EPS VS EstimatesASMB Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -10 -20 -30 -40

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • ASMB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ASMB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ASMB Price Earnings VS Forward Price EarningsASMB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ASMB Per share dataASMB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ASMB's earnings are expected to grow with 32.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.3%
EPS Next 3Y32.01%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ASMB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ASSEMBLY BIOSCIENCES INC

NASDAQ:ASMB (2/27/2026, 8:00:02 PM)

After market: 29.84 0 (0%)

29.84

+0.25 (+0.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-18
Inst Owners50.62%
Inst Owner Change16.01%
Ins Owners3.79%
Ins Owner Change0%
Market Cap472.07M
Revenue(TTM)37.19M
Net Income(TTM)-38.55M
Analysts86
Price Target46.67 (56.4%)
Short Float %15.21%
Short Ratio12.95
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.68%
Min EPS beat(2)4.47%
Max EPS beat(2)8.89%
EPS beat(4)4
Avg EPS beat(4)16.56%
Min EPS beat(4)4.47%
Max EPS beat(4)28.31%
EPS beat(8)8
Avg EPS beat(8)22.79%
EPS beat(12)8
Avg EPS beat(12)13.05%
EPS beat(16)10
Avg EPS beat(16)10.76%
Revenue beat(2)2
Avg Revenue beat(2)46.25%
Min Revenue beat(2)41.79%
Max Revenue beat(2)50.71%
Revenue beat(4)4
Avg Revenue beat(4)39.05%
Min Revenue beat(4)24.54%
Max Revenue beat(4)50.71%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.19%
PT rev (3m)19.76%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)8.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-25%
Revenue NY rev (1m)0%
Revenue NY rev (3m)16.66%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.69
P/FCF N/A
P/OCF N/A
P/B 2.58
P/tB 2.58
EV/EBITDA N/A
EPS(TTM)-4.79
EYN/A
EPS(NY)-3.55
Fwd EYN/A
FCF(TTM)-3.53
FCFYN/A
OCF(TTM)-3.52
OCFYN/A
SpS2.35
BVpS11.55
TBVpS11.55
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -16.06%
ROE -21.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.64%
ROA(5y)-51.96%
ROE(3y)-127.35%
ROE(5y)-96.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 32.56%
Cap/Sales 0.11%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.44
Quick Ratio 4.44
Altman-Z 0.44
F-Score4
WACC8.61%
ROIC/WACCN/A
Cap/Depr(3y)32.95%
Cap/Depr(5y)216.9%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.32%
EPS Next Y45.91%
EPS Next 2Y21.3%
EPS Next 3Y32.01%
EPS Next 5Y11.4%
Revenue 1Y (TTM)31.3%
Revenue growth 3Y65.83%
Revenue growth 5Y12.31%
Sales Q2Q%57.62%
Revenue Next Year38.92%
Revenue Next 2Y-9.79%
Revenue Next 3Y45.02%
Revenue Next 5Y19.24%
EBIT growth 1Y6.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.76%
EBIT Next 3Y38.47%
EBIT Next 5Y28.3%
FCF growth 1Y20.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.56%
OCF growth 3YN/A
OCF growth 5YN/A

ASSEMBLY BIOSCIENCES INC / ASMB FAQ

What is the ChartMill fundamental rating of ASSEMBLY BIOSCIENCES INC (ASMB) stock?

ChartMill assigns a fundamental rating of 3 / 10 to ASMB.


Can you provide the valuation status for ASSEMBLY BIOSCIENCES INC?

ChartMill assigns a valuation rating of 1 / 10 to ASSEMBLY BIOSCIENCES INC (ASMB). This can be considered as Overvalued.


How profitable is ASSEMBLY BIOSCIENCES INC (ASMB) stock?

ASSEMBLY BIOSCIENCES INC (ASMB) has a profitability rating of 1 / 10.


What is the earnings growth outlook for ASSEMBLY BIOSCIENCES INC?

The Earnings per Share (EPS) of ASSEMBLY BIOSCIENCES INC (ASMB) is expected to grow by 45.91% in the next year.